Combined elevation of pre-treatment γ-glutamyltransferase and lactate dehydrogenase as independent prognosticator for metastatic renal cell carcinoma undergoing immune-based therapy.

When patients are diagnosed with advanced kidney cancer, formally known as metastatic renal cell carcinoma, doctors often turn to treatments that harness the immune system to fight the disease. A major challenge in this process is predicting how individual patients will fare over time. Now, researchers have found that looking at two routine blood markers before treatment begins can help forecast patient survival.

The researchers focused on two specific enzymes commonly measured in standard blood panels: lactate dehydrogenase (LDH) and gamma-glutamyltransferase (GGT). By looking at the records of 240 patients treated in real-world clinic settings, the team discovered a strong pattern. Patients with low baseline levels of LDH went significantly longer before their cancer progressed. Even better, patients who had low levels of both LDH and GGT lived longer overall. Conversely, when both of these enzymes were elevated at the same time, patients faced a higher risk of their disease worsening and a higher overall mortality rate.

Interestingly, the researchers noted that these enzymes could not predict whether the tumors would initially shrink in response to the therapy. Instead, combining the results of these two tests gave doctors a much sharper lens for viewing long-term survival trends, proving more powerful than looking at either marker alone.